---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-007011"
form_type: "8-K"
ticker: "PBSV"
cik: "0001304161"
company_name: "Pharma-Bio Serv, Inc."
filed_at: "2025-06-16T23:59:59+00:00"
generated_at: "2026-05-19T06:10:32.548421+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Pharma-Bio Serv reports Q2 net income of $0.1M, reversing prior-year loss

## Summary
- Q2 revenue $2.4M (vs $2.3M YoY); six-month revenue $4.9M (vs $4.8M YoY).
- Net income for Q2 and first half $0.1M each, up $0.3M and $0.6M vs prior-year losses.
- CEO cites focus on high-margin projects as driver of improved profitability.
- No guidance provided; OTCQB ticker PBSV remains unchanged.

## SEC filing metadata
- accession: 0001654954-25-007011
- form_type: 8-K
- ticker: PBSV
- cik: 0001304161
- company_name: Pharma-Bio Serv, Inc.
- filed_at: 2025-06-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1304161/000165495425007011/0001654954-25-007011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1304161/000165495425007011/pbsv_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-007011
- JSON: https://secwatch.observer/filing/0001654954-25-007011.json
- Plain text: https://secwatch.observer/filing/0001654954-25-007011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.